Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the sale, the director now directly owns 472,207 shares of the company’s stock, valued at $7,635,587.19. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Tyra Biosciences Trading Down 1.7 %
NASDAQ TYRA traded down $0.29 during trading hours on Friday, reaching $16.39. 523,453 shares of the company traded hands, compared to its average volume of 186,846. Tyra Biosciences, Inc. has a 12 month low of $10.60 and a 12 month high of $29.60. The stock has a market capitalization of $865.56 million, a PE ratio of -9.70 and a beta of 1.01. The company has a 50 day moving average of $22.51 and a two-hundred day moving average of $19.87.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the stock. Piper Sandler started coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Wedbush restated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Oppenheimer upped their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Finally, HC Wainwright upped their target price on shares of Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $31.40.
Get Our Latest Analysis on Tyra Biosciences
Tyra Biosciences Company Profile
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Articles
- Five stocks we like better than Tyra Biosciences
- What is the NASDAQ Stock Exchange?
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- How is Compound Interest Calculated?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Manufacturing Stocks Investing
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.